Buprenex Side Effects

Generic name: buprenorphine

Medically reviewed by Philip Thornton, DipPharm. Last updated on Apr 9, 2025.

Note: This document provides detailed information about Buprenex Side Effects associated with buprenorphine. Some dosage forms listed on this page may not apply specifically to the brand name Buprenex.

Applies to buprenorphine: film, tablet.

Other dosage forms:

• injection solution
• intradermal implant
• transdermal patch extended release

Important warnings This medicine can cause some serious health issues

Buccal mucosa route (film)

Addiction, Abuse, and Misuse. Buprenorphine exposes patients and other users to the risks of opioid addiction, abuse, and misuse, which can lead to overdose and death.

Assess each patient's risk prior to prescribing buprenorphine, and monitor all patients regularly for the development of these behaviors or conditions.Opioid Analgesic Risk Evaluation and Mitigation Strategy (REMS)To ensure that the benefits of opioid analgesics outweigh the risks of addiction, abuse and misuse, the Food and Drug Administration (FDA) has required a REMS for these products.

Under the requirements of the REMS, drug companies with approved opioid analgesic products must make REMS-compliant education programs available to healthcare providers.

Healthcare providers are strongly encouraged to: complete a REMS-compliant education program, counsel patients and/or their caregivers, with every prescription, on safe use, serious risks, storage, and disposal of these products, emphasize to patients and their caregivers the importance of reading the Medication Guide every time it is provided by their pharmacists, and consider other tools to improve patient, household, and community safety.Life-Threatening Respiratory Depression. Serious, life-threatening, or fatal respiratory depression may occur with use of buprenorphine.

Monitor for respiratory depression, especially during initiation of buprenorphine or following a dose increase.

Misuse or abuse of buprenorphine by chewing, swallowing, snorting or injecting buprenorphine extracted from the buccal film will result in the uncontrolled delivery of buprenorphine and pose a significant risk of overdose and death.Accidental Exposure. Accidental exposure to even one dose of buprenorphine, especially by children, can result in a fatal overdose of buprenorphine.Neonatal Opioid Withdrawal Syndrome. Prolonged use of buprenorphine during pregnancy can result in neonatal opioid withdrawal syndrome, which may be life-threatening if not recognized and treated, and requires management according to protocols developed by neonatology experts.

If opioid use is required for a prolonged period in a pregnant woman, advise the patient of the risk of neonatal opioid withdrawal syndrome and ensure that appropriate treatment will be available.Risks from Concomitant Use with Benzodiazepines or Other CNS Depressants. Reserve concomitant prescribing of buprenorphine and benzodiazepines or other CNS depressants for use in patients for whom alternative treatment options are inadequate.

Limit dosages and durations to the minimum required.

Follow patients for signs and symptoms of respiratory depression and sedation.

Precautions

It is very important that your doctor check your progress while you are using this medicine, especially within the first 24 to 72 hours of treatment. This will allow your doctor to see if the medicine is working properly and to decide if you should continue to take it. Blood and urine tests may be needed to check for unwanted effects.

It is against the law and dangerous for anyone else to use your medicine. Keep your unused tablets and buccal films in a safe and secure place. People who are addicted to drugs might want to steal this medicine.

Do not use this medicine if you have used an MAO inhibitor (MAOI) (eg, isocarboxazid [Marplan®], linezolid [Zyvox®], phenelzine [Nardil®], selegiline [Eldepryl®], tranylcypromine [Parnate®]) within the past 14 days.

Using too much buprenorphine (the active ingredient contained in Buprenex) may cause an overdose. Symptoms of overdose include: change in consciousness, chest pain, cold and clammy skin, increased sweating coughing that sometimes produces a pink frothy sputum, difficult or trouble breathing, increased sweating, irregular, fast or slow, or shallow breathing, loss of consciousness, pale or blue lips, fingernails, or skin, sleepiness or unusual drowsiness, or swelling in legs and ankles. Your doctor may give you naloxone to treat an overdose.

This medicine may cause sleep-related breathing problems (eg, sleep apnea, sleep-related hypoxemia). Your doctor may decrease your dose if you have sleep apnea (stop breathing for short periods during sleep) while using this medicine.

This medicine may cause serious tooth problems. Tell your doctor right away if you have cavities, tooth decay, tooth pain, tooth infection, tooth erosion, tooth fracture, or tooth loss.

Before having any kind of surgery (including dental surgery) or emergency treatment, tell the medical doctor or dentist in charge that you are using this medicine. Serious unwanted effects can occur if certain medicines are given together with buprenorphine.

This medicine will add to the effects of alcohol and other central nervous system (CNS) depressants (medicines that make you drowsy or less alert). Some examples of CNS depressants are antihistamines or medicine for hay fever, allergies, or colds, sedatives, benzodiazepines, tranquilizers, or sleeping medicine, other prescription pain medicine or narcotics, medicine for seizures or barbiturates, muscle relaxants, or anesthetics (numbing medicines), including some dental anesthetics. Check with your doctor or dentist before taking any of the medicines listed above while you are using this medicine.

Dizziness, lightheadedness, or fainting may occur when you get up suddenly from a lying or sitting position. Getting up slowly may help. Also, lying down for a while may relieve the dizziness or lightheadedness.

This medicine may make you dizzy, drowsy, or lightheaded. Do not drive or do anything else that could be dangerous until you know how this medicine affects you.

This medicine may cause serious allergic reactions, including anaphylaxis, which can be life-threatening and require immediate medical attention. Call your doctor right away if you have a rash, itching, hoarseness, trouble breathing, trouble swallowing, or any swelling of your hands, face, or mouth while you are using this medicine.

Check with your doctor right away if you have darkening of the skin, diarrhea, dizziness, fainting, loss of appetite, mental depression, nausea, skin rash, unusual tiredness or weakness, or vomiting. These may be symptoms of adrenal gland problem.

Contact your doctor right away if you have any changes to your heart rhythm. You might feel dizzy or faint, or you might have a fast, pounding, or uneven heartbeat. Make sure your doctor knows if you or anyone in your family has ever had a heart rhythm problem such as QT prolongation.

Belbuca® may be habit-forming. If you feel that the medicine is not working as well, do not use more than your prescribed dose. Call your doctor for instructions.

Using narcotics for a long time can cause severe constipation. To prevent this, your doctor may direct you to take laxatives, drink a lot of fluids, or increase the amount of fiber in your diet. Be sure to follow the directions carefully, because continuing constipation can lead to more serious problems.

If you have been using this medicine regularly for several weeks or longer, do not change your dose or suddenly stop using it without checking first with your doctor. Your doctor may want you to gradually reduce the amount you are using before stopping it completely. This may help reduce the possibility of withdrawal symptoms, including stomach cramps, anxiety, fever, nausea, runny nose, sweating, tremors, or trouble with sleeping.

Using this medicine while you are pregnant may cause serious unwanted effects, including neonatal opioid withdrawal syndrome in your newborn baby. Tell your doctor right away if you think you are pregnant or if you plan to become pregnant while using this medicine.

For nursing mothers taking Belbuca®:

• Talk to your doctor if you have any questions about taking oxycodone or about how this medicine may affect your baby.
• Call your doctor if you become extremely tired and have difficulty caring for your baby.
• Your baby should generally nurse every 2 to 3 hours and should not sleep for more than 4 hours at a time.
• Check with your doctor or hospital emergency room immediately if your baby shows signs of increased sleepiness (more than usual), difficulty breastfeeding, difficulty breathing, or limpness. These may be symptoms of an overdose and need immediate medical attention.

Using too much of this medicine may cause reduced infertility (unable to have children). Talk with your doctor before using this medicine if you plan to have children.

Check with your doctor right away if you have pain or tenderness in the upper stomach, pale stools, dark urine, loss of appetite, nausea, vomiting, or yellow eyes or skin. These could be symptoms of a serious liver problem.

Check with your doctor right away if you have anxiety, restlessness, a fast heartbeat, fever, sweating, muscle spasms, twitching, nausea, vomiting, diarrhea, or see or hear things that are not there. These may be symptoms of a serious condition called serotonin syndrome. Your risk may be higher if you also take certain other medicines that affect serotonin levels in your body.

Do not take other medicines unless they have been discussed with your doctor. This includes prescription or nonprescription (over-the-counter [OTC]) medicines and herbal or vitamin supplements.

Common side effects of Buprenex

Some side effects of buprenorphine may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.

Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

More common side effects

• back pain
• chills
• cough
• difficulty having a bowel movement
• hoarseness
• painful or difficult urination
• runny nose
• sneezing
• stuffy nose
• trouble sleeping

Less common side effects

• anxiety
• back pain
• bruise
• decreased appetite
• fall
• feeling of warmth or heat
• flushing or redness of the skin, especially on the face and neck
• itching, skin rash
• muscle aches or spams
• pain or tenderness around eyes and cheekbones
• sore throat

Rare side effects

• lack or loss of strength
• muscle or bone pain
• neck pain
• stomach discomfort

Serious side effects of Buprenex

Along with its needed effects, buprenorphine may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor immediately if any of the following side effects occur while taking buprenorphine:

Less common side effects

• bladder pain
• bloating or swelling of the face, arms, hands, lower legs, or feet
• bloody or cloudy urine
• blurred vision
• chest tightness
• cough producing mucus
• diarrhea
• difficult, burning, or painful urination
• difficulty breathing
• dizziness
• fever
• frequent urge to urinate
• headache
• loss of appetite
• lower back or side pain
• mouth or throat pain
• nausea
• nervousness
• pale skin
• pounding in the ears
• rapid weight gain
• slow or fast heartbeat
• stomach pain
• tingling of the hands or feet
• trouble breathing
• unusual bleeding or bruising
• unusual tiredness or weakness
• unusual weight gain or loss

Rare side effects

• breakdown or tearing of the skin
• chills
• irregular heartbeat, recurrent
• irritation, itching, pain, redness, swelling, tenderness, or warmth on the skin
• unusual drowsiness, dullness, or feeling of sluggishness

Incidence not known

• agitation
• burning, crawling, itching, numbness, prickling, "pins and needles", or tingling feelings
• blurred vision
• confusion
• cough
• darkening of the skin
• difficulty swallowing
• dizziness, faintness, or lightheadedness when getting up suddenly from a lying or sitting position
• drowsiness
• headache, severe and throbbing
• hives, skin rash
• irregular, fast, slow, or shallow breathing
• mental depression
• overactive reflexes
• pale or blue lips, fingernails, or skin
• pinpoint pupils
• poor coordination
• puffiness or swelling of the eyelids or around the eyes, face, lips, or tongue
• relaxed and calm feeling
• restlessness
• shivering
• sleepiness
• talking or acting with excitement you cannot control
• toothache
• trembling or shaking
• twitching
• vomiting

Get emergency help immediately if any of the following symptoms of overdose occur while taking buprenorphine:

Symptoms of overdose

• change in consciousness
• chest pain
• cold and clammy skin
• increased sweating
• coughing that sometimes produces a pink frothy sputum
• difficult or trouble breathing
• increased sweating
• irregular, fast or slow, or shallow breathing
• loss of consciousness
• pale or blue lips, fingernails, or skin
• sleepiness or unusual drowsiness
• swelling in legs and ankles

For healthcare professionals

Applies to buprenorphine: buccal film, compounding powder, injectable solution, subcutaneous solution extended release, subdermal implant, sublingual tablet, transdermal film extended release.

Cardiovascular adverse events

• Common (1% to 10%): Circulatory collapse, circulatory disorders, ECG prolonged QT, flushing, hot flush, hypertension, hypotension, orthostatic hypotension, palpitations, tachycardia, vasodilatation, vasodilation
• Uncommon (0.1% to 1%): Angina pectoris, bradycardia, cyanosis, heat stroke, myocardial infarction, pallor, second degree atrioventricular block
• Rare (0.01% to 0.1%): Hot flushes
• Frequency not reported: Atrial fibrillation, coronary artery disease, fainting, fall in blood pressure, increased blood pressure, prolonged QTc, Wenckebach block
• Postmarketing reports: Heart rate/rhythm disorders, hypotension, orthostatic hypotension

Circulatory disorders included hypotension and rarely, circulatory collapse.

Dermatologic

• Very common (10% or more): Sweating (up to 13%), erythema, hyperhidrosis/sweating, pruritus
• Common (1% to 10%): Cellulitis, diaphoresis, exanthema, excoriation, generalized pruritus, laceration, rash, subcutaneous abscess, urticaria
• Uncommon (0.1% to 1%): Acne, alopecia, dry skin, exfoliative dermatitis, macular rash, scratch, skin lesion, skin mass
• Very rare (less than 0.01%): Pustules, vesicles
• Frequency not reported: Angioedema (Quincke's edema)/angioneurotic edema, contact dermatitis, skin discoloration, urticaria/hives
• Postmarketing reports: Angioneurotic edema, hyperhidrosis, pruritus, rash

Endocrine

• Frequency not reported: Decreased blood testosterone

Opioids:

• Postmarketing reports: Adrenal insufficiency, androgen deficiency

Cases of adrenal insufficiency have been reported with opioid use, more often when used beyond 1 month. Cases of androgen deficiency have occurred with prolonged opioid use.

Gastrointestinal

• Very common (10% or more): Nausea (up to 50%), constipation (up to 14%), abdominal pain (up to 11.7%), diarrhea (up to 10.3%), dry mouth, vomiting
• Common (1% to 10%): Dyspepsia, flatulence, gastroenteritis, gastrointestinal disorder, increased lipase, oral herpes, stomach discomfort, tooth abscess, tooth disorder, tooth infection, toothache, upper abdominal pain, viral gastroenteritis
• Uncommon (0.1% to 1%): Tongue discoloration, mouth ulceration
• Rare (0.01% to 0.1%): Diverticulitis, dysphagia, ileus, pyrosis/heartburn
• Very rare (less than 0.01%): Retching
• Frequency not reported: Abdominal discomfort, abdominal distention
• Postmarketing reports: Dental decay, nausea, vomiting

According to some authorities, females reported nausea and vomiting 10% to 15% more frequently than males.

Dental decay included caries, tooth fracture, and tooth loss.

Cases of dental caries, some severe (i.e., tooth fracture, tooth loss), have been reported after the use of transmucosal buprenorphine-containing products. Reported events included cavities, tooth decay, dental abscesses/infection, rampant caries, tooth erosion, fillings falling out, and, in some cases, total tooth loss.

Genitourinary

• Common (1% to 10%): Dysmenorrhea, erectile dysfunction, urinary aberration, urinary retention, urinary tract infection
• Uncommon (0.1% to 1%): Albuminuria, amenorrhea, dysuria, ejaculation disorder, hematuria, intermenstrual bleeding, menorrhagia, micturition disorders, urinary hesitation, urinary incontinence, vaginal infection
• Rare (0.01% to 0.1%): Decreased erection, sexual dysfunction
• Postmarketing reports: Urinary retention

Hematologic

• Common (1% to 10%): Anemia, lymphadenopathy
• Uncommon (0.1% to 1%): Leukocytosis, leukopenia, thrombocytopenia

Hepatic

• Very common (10% or more): Increased ALT (12.4%), increased AST (up to 11.4%)
• Common (1% to 10%): Abnormal liver enzymes, abnormal liver function tests, increased GGT, increased hepatic enzymes
• Uncommon (0.1% to 1%): Hepatic necrosis, hepatitis
• Rare (0.01% to 0.1%): Biliary colic
• Frequency not reported: Abnormal hepatic function, abnormal liver function test, acute hepatitis, cholecystitis, cytolytic hepatitis, hepatic abnormalities, hepatitis with jaundice, hepatorenal syndrome, increased intracholedochal pressure, increased transaminases, jaundice
• Postmarketing reports: Elevated hepatic transaminases, hepatic encephalopathy, hepatic failure, hepatic necrosis, hepatitis, hepatorenal syndrome, jaundice

Increased ALT (greater than 3 times the upper limit of normal [3 x ULN]) and increased AST (greater than 3 x ULN) have been reported in up to 12.4% and up to 11.4% of patients, respectively.

Increased hepatic enzymes included increased hepatic enzymes, abnormal liver function test, and elevated ALT, AST, GGT, alkaline phosphatase, and/or bilirubin.

The spectrum of hepatic abnormalities ranged from transient asymptomatic elevations in hepatic transaminases to case reports of death, hepatic failure, hepatic necrosis, hepatorenal syndrome, and hepatic encephalopathy.

Hypersensitivity

• Common (1% to 10%): Hypersensitivity
• Uncommon (0.1% to 1%): Allergic reaction
• Rare (0.01% to 0.1%): Anaphylactic reaction
• Very rare (less than 0.01%): Serious allergic reactions
• Frequency not reported: Anaphylactic shock, anaphylactoid reaction, drug hypersensitivity
• Postmarketing reports: Anaphylactic shock, anaphylaxis

Cases of acute and chronic hypersensitivity to this drug have been reported in clinical trials and during postmarketing experience. The most common signs/symptoms included rashes, hives, and pruritus; cases of bronchospasm, angioneurotic edema, and anaphylactic shock have been reported.

Allergic reaction included oropharyngeal swelling and swollen tongue.

Serious allergic reactions have been reported; in some cases, delayed allergic reactions occurred with marked signs of inflammation.

Local

• Very common (10% or more): Administration site reactions (up to 20.7%), application site pruritus (up to 15%), implant site pain (up to 13%), implant site pruritus (up to 12%), implant site erythema (10.4%), application site erythema, application site reaction, application site skin reactions
• Common (1% to 10%): Application site irritation, application site rash, implant site edema, implant site hematoma, implant site hemorrhage, injection site bruising, injection site erythema, injection site induration, injection site inflammation, injection site mass, injection site pain, injection site pruritus, injection site reaction, injection site swelling, injection site ulcer
• Uncommon (0.1% to 1%): Injection site cellulitis, injection site discomfort, injection site edema, injection site infection, injection site urticaria, local swelling
• Rare (0.01% to 0.1%): Administration site reactions
• Frequency not reported: Application site dermatitis, application site skin discoloration
• Postmarketing reports: Injection site abscess, injection site mass, injection site necrosis, injection site ulceration

Application site reaction included erythema, edema, pruritus, or rash at the application site.

Application site skin reactions included common signs/symptoms of contact dermatitis (irritative/allergic), erythema, edema, pruritus, rash, vesicles, and pain/burning sensation at the application site. In some cases, late-onset local allergic reactions (allergic contact dermatitis) occurred with marked signs of inflammation.

In rare cases, severe application site skin reactions with signs of marked inflammation (including burn, discharge, and vesicles) have occurred.

Cases of injection site abscess, ulceration, and necrosis have been reported after treatment initiation. Some cases required debridement and antibiotic treatment.

Metabolic

• Common (1% to 10%): Anorexia, decreased appetite/appetite loss, increased blood glucose
• Uncommon (0.1% to 1%): Dehydration, hyperglycemia, hyperlipidemia, hypoglycemia

Opioids:

• Postmarketing reports: Hypoglycemia

Cases of hypoglycemia have been reported in patients taking opioids; most reports were in those with at least 1 predisposing risk factor (e.g., diabetes).

Musculoskeletal

• Very common (10% or more): Back pain (up to 16%)
• Common (1% to 10%): Arthralgia, bone pain, increased blood creatine phosphokinase, joint swelling, leg cramps, ligament sprain, muscle spasms, muscle twitching, muscular weakness, musculoskeletal pain, myalgia, neck pain, pain in extremity
• Uncommon (0.1% to 1%): Arthritis, muscle cramps, muscle strain
• Frequency not reported: Ankle fracture, muscle aches, muscle weakness, osteoarthritis

Nervous system

• Very common (10% or more): Headache (up to 34%), dizziness (up to 15%), somnolence (up to 13%), drowsiness, sedation, sleep, vertigo
• Common (1% to 10%): Dysgeusia/taste disturbance, hypertonia, hypoesthesia, lethargy, migraine, paresthesia, speech disorders, syncope, tremor
• Uncommon (0.1% to 1%): Abnormal coordination, amnesia, coma, concentration impairment, disturbance in attention, dysarthria, dysgeusia/parageusia, exhaustion, hyperkinesia, impaired speech, lack of muscle coordination, memory impairment, paresthesia (e.g., pricking/burning skin sensation), procedural dizziness, seizure, slurred speech, tinnitus
• Rare (0.01% to 0.1%): Balance disorder, convulsions, disequilibrium, impaired concentration, numbness, seizures, speech disorder
• Very rare (less than 0.01%): Involuntary muscle contractions, muscle fasciculation
• Frequency not reported: Cerebrovascular accident, depressed level of consciousness, dysgeusia, gait disturbance, hyperalgesia, loss of consciousness, mental impairment, postural dizziness, sleep apnea syndrome, sleepiness, transient ischemic attack
• Postmarketing reports: Coma, convulsions, dizziness, headache, neonatal tremor, somnolence, vertigo

Opioids:

• Postmarketing reports: Serotonin syndrome, hyperalgesia, allodynia

According to some authorities, females reported dizziness and headache 10% to 15% more frequently than males.

In clinical studies involving 1133 patients, sedation occurred in about two-thirds of the patients.

Serotonin syndrome (a potentially life-threatening condition) has been reported during concomitant use of opioids with serotonergic drugs.

Hyperalgesia and allodynia have been reported with opioid therapy of any duration.

Ocular

• Common (1% to 10%): Amblyopia, lacrimal disorder, lacrimation disorders, miosis, mydriasis, runny eyes, tears disturbance
• Uncommon (0.1% to 1%): Blurred vision, conjunctivitis, diplopia, dry eye, visual impairment
• Rare (0.01% to 0.1%): Eyelid edema, visual disturbance
• Frequency not reported: Visual abnormalities
• Postmarketing reports: Miosis

Other

• Very common (10% or more): Pain (up to 26%), withdrawal syndrome (up to 24%), infection (up to 22%), asthenia (up to 16%), drug withdrawal syndrome, tiredness
• Common (1% to 10%): Abscess, accidental injury, accidental overdose, asthenic conditions, chest pain, chills, contusion, decreased weight, ear pain, edema, fall, fatigue, fever, increased weight, injury, limb injury, malaise, neonatal drug withdrawal syndrome, peripheral edema, pyrexia, road traffic accident, viral infection, weight loss
• Uncommon (0.1% to 1%): Accidental injury (including fall), chills/cold, face edema, feeling cold, hypothermia, influenza-like illness, noncardiac chest pain, rigors, warmth, weariness
• Rare (0.01% to 0.1%): Withdrawal symptoms
• Very rare (less than 0.01%): Thoracic pain
• Frequency not reported: Drug ineffective, drug interactions, drug tolerance, weakness
• Postmarketing reports: Deaths, decreased weight, drug ineffective, drug interaction, drug misuse, drug withdrawal reactions, drug withdrawal syndrome, fatigue, fetal disorders, IV/intentional misuse, neonatal withdrawal syndrome, peripheral edema

Buprenorphine-naloxone sublingual tablets:

• Postmarketing reports: Peripheral edema

The most common adverse events reported were those related to withdrawal symptoms (e.g., abdominal pain, headache, pain, diarrhea, nausea, muscle aches, anxiety, sweating).

Asthenic conditions included muscle weakness, lethargy, fatigue, and malaise.

Accidental injury included fall.

Withdrawal symptoms included agitation, anxiety, nervousness, insomnia, hyperkinesia, tremor, and gastrointestinal disorders.

During treatment of opioid use disorder, cases of drug withdrawal reactions consistent with insufficient drug dosing have been reported; cases often occurred at or after 2 weeks of treatment initiation and resolved upon dose increase.

In cases of IV or intentional misuse, local reactions (e.g., cellulitis, abscess) that were sometimes septic, potentially serious acute hepatitis, pneumonia, endocarditis, and other serious infections have been reported.

Psychiatric

• Very common (10% or more): Insomnia (up to 28%), anxiety (up to 14%), depression (up to 13%)
• Common (1% to 10%): Abnormal thinking, agitation, confusion, decreased libido, hallucinations, hostility, medical dependence, nervousness, paranoia
• Uncommon (0.1% to 1%): Abnormal dreaming, affect lability, aggression, apathy, confusional state, depersonalization, disorientation, dreaming, euphoria/euphoric mood, euphoric mood, euphoric mood/euphoria, nightmare, psychosis, psychotic disorder, restlessness, sleep disorder
• Rare (0.01% to 0.1%): Dysphoria, psychomimetic effects (e.g., hallucinations, anxiety, nightmares)
• Very rare (less than 0.01%): Dependence, mood swings
• Frequency not reported: Confusional state/confusion, depressed mood, drug dependence, mental status changes, psychotic disorder/psychosis
• Postmarketing reports: Confusional state, drug abuse, drug dependence, hallucinations, neonatal feeding disorder

Renal

• Uncommon (0.1% to 1%): Increased blood creatinine, nephrolithiasis

Respiratory

• Very common (10% or more): Rhinitis (up to 15%), influenza syndrome (up to 10.2%)
• Common (1% to 10%): Asthma, bronchitis, cough, dyspnea, hypoventilation, increased cough, influenza, nasal congestion, nasopharyngitis, oropharyngeal pain, pharyngitis, pharyngolaryngeal pain, pneumonia, sinus congestion, sinusitis, upper respiratory tract infection, yawning
• Uncommon (0.1% to 1%): Apnea, asthma aggravated, hiccups, hyperventilation, hypoxia, respiratory depression, wheezing
• Rare (0.01% to 0.1%): Respiratory failure
• Frequency not reported: Abnormal respiration, acute sinusitis, bronchospasm, respiratory distress, rhinorrhea
• Postmarketing reports: Asphyxia, bronchospasm, hypoventilation, respiratory depression

Opioids:

• Frequency not reported: Respiratory depression, sleep-related breathing disorders (including central sleep apnea, sleep-related hypoxemia)

Serious, life-threatening, or fatal respiratory depression has been reported with opioid use, even when used as recommended.

See also:

Frequently asked questions

• What are the different brands of buprenorphine?
• Is buprenorphine an opiate / narcotic?
• Is Buprenex the same as buprenorphine?
• Is Buprenex safe for humans?
• How long does Buprenex stay in your system?
• How long does opioid withdrawal last?
• How long does buprenorphine stay in your system?

Further information

Buprenex side effects can vary depending on the individual. Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Note: Medication side effects may be underreported. If you are experiencing side effects that are not listed, submit a report to the FDA by following this guide.

Medical Disclaimer